Moxham CM - Search Results

1

Conditional, tissue-specific expression of Q205L G alpha i2 in vivo mimics insulin action.

Chen JF, Guo JH, Moxham CM, Wang HY, Malbon CC. Chen JF, et al. Among authors: moxham cm. J Mol Med (Berl). 1997 Apr;75(4):283-9. doi: 10.1007/s001090050113. J Mol Med (Berl). 1997. PMID: 9151214

2

Gi alpha 2 mediates the inhibitory regulation of adenylylcyclase in vivo: analysis in transgenic mice with Gi alpha 2 suppressed by inducible antisense RNA.

Moxham CM, Hod Y, Malbon CC. Moxham CM, et al. Dev Genet. 1993;14(4):266-73. doi: 10.1002/dvg.1020140404. Dev Genet. 1993. PMID: 7693386

3

Suppression of Gi alpha 2 enhances phospholipase C signalling.

Watkins DC, Moxham CM, Morris AJ, Malbon CC. Watkins DC, et al. Among authors: moxham cm. Biochem J. 1994 May 1;299 ( Pt 3)(Pt 3):593-6. doi: 10.1042/bj2990593. Biochem J. 1994. PMID: 8192647 Free PMC article.

4

Induction of G alpha i2-specific antisense RNA in vivo inhibits neonatal growth.

Moxham CM, Hod Y, Malbon CC. Moxham CM, et al. Science. 1993 May 14;260(5110):991-5. doi: 10.1126/science.8493537. Science. 1993. PMID: 8493537

5

Insulin action impaired by deficiency of the G-protein subunit G ialpha2.

Moxham CM, Malbon CC. Moxham CM, et al. Nature. 1996 Feb 29;379(6568):840-4. doi: 10.1038/379840a0. Nature. 1996. PMID: 8587610

6

Induction of Galphaq-specific antisense RNA in vivo causes increased body mass and hyperadiposity.

Galvin-Parton PA, Chen X, Moxham CM, Malbon CC. Galvin-Parton PA, et al. Among authors: moxham cm. J Biol Chem. 1997 Feb 14;272(7):4335-41. doi: 10.1074/jbc.272.7.4335. J Biol Chem. 1997. PMID: 9020153 Free article.

7

Jun N-terminal kinase mediates activation of skeletal muscle glycogen synthase by insulin in vivo.

Moxham CM, Tabrizchi A, Davis RJ, Malbon CC. Moxham CM, et al. J Biol Chem. 1996 Nov 29;271(48):30765-73. doi: 10.1074/jbc.271.48.30765. J Biol Chem. 1996. PMID: 8940056 Free article.

8

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.

Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, Wang G, Inigo I, Surguladze D, Pennello AL, Persaud K, Hindi S, Topper M, Chen X, Zhang Y, Bulaon DK, Bailey T, Lao Y, Han B, Torgerson S, Chin D, Sonyi A, Haidar JN, Novosiadly RD, Moxham CM, Plowman GD, Ludwig DL, Kalos M. Kotanides H, et al. Among authors: moxham cm. Cancer Immunol Res. 2020 Oct;8(10):1300-1310. doi: 10.1158/2326-6066.CIR-20-0304. Epub 2020 Jul 27. Cancer Immunol Res. 2020. PMID: 32873605

9

Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.

Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ. Regmi A, et al. Bone. 2005 Feb;36(2):284-91. doi: 10.1016/j.bone.2004.09.022. Bone. 2005. PMID: 15780954

10

Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.

Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ. Lee JA, et al. Among authors: moxham cm. J Med Chem. 2012 May 24;55(10):4527-38. doi: 10.1021/jm201649s. Epub 2012 Mar 23. J Med Chem. 2012. PMID: 22409666 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page